BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12753151)

  • 1. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
    Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
    J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
    Suspiro A; Pereira AD; Afonso A; Albuquerque C; Chaves P; Soares J; Leitão CN
    Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
    Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
    Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Walch A; Mueller J; Höfler H; Werner M
    J Natl Cancer Inst; 2000 Jul; 92(14):1182-3. PubMed ID: 10904093
    [No Abstract]   [Full Text] [Related]  

  • 7. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
    Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
    Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations in malignant and premalignant Barrett's esophagus.
    Dolan K; Walker SJ; Gosney J; Field JK; Sutton R
    Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of loss of heterozygosity on chromosome 17 during the progression to barrett's adenocarcinoma involves a unique combination of target sites in individual specimens.
    Dunn JR; Garde J; Dolan K; Gosney JR; Oates BC; Watson AJ; Fielding P; Field JK
    Clin Cancer Res; 2000 Oct; 6(10):4033-42. PubMed ID: 11051253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
    Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
    Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
    Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus.
    Eluri S; Brugge WR; Daglilar ES; Jackson SA; Styn MA; Callenberg KM; Welch DC; Barr TM; Duits LC; Bergman JJ; Shaheen NJ
    Am J Gastroenterol; 2015 Jun; 110(6):828-34. PubMed ID: 26010308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.